Parcopa vs Rytary (IPX066)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Parcopa

Rights held by UCB; US product discontinued

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT00139867 · Phase 3 · completed

The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)

Result source: NCT00139880

Rytary (IPX066)

Marketed by Amneal Pharmaceuticals

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT00974974 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).

Reported efficacy

Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)

Result source: NCT00974974

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointParcopaRytary (IPX066)
OFF time, change—Not posted · NCT00139880—Not reported
ON time without troublesome dyskinesia, change—Not posted · NCT00139880—Not reported
UPDRS Part III, change—Not posted · NCT0013988021.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791
MDS-UPDRS Part II, change—Not posted · NCT00139880—Not reported

OFF time, change

Parcopa
—Not posted · NCT00139880
Rytary (IPX066)
—Not reported

ON time without troublesome dyskinesia, change

Parcopa
—Not posted · NCT00139880
Rytary (IPX066)
—Not reported

UPDRS Part III, change

Parcopa
—Not posted · NCT00139880
Rytary (IPX066)
21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791

MDS-UPDRS Part II, change

Parcopa
—Not posted · NCT00139880
Rytary (IPX066)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Parcopa: 2 of 4 rows · Rytary (IPX066): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricParcopaRytary (IPX066)
Dropout rate
—a
NCT00590122 · Phase 4 · registry result, not featured evidence
—b
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
24.5%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
20.2%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
17.2%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
8.1%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00590122 · Phase 4 · registry result, not featured evidence
—b
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
15.3%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
14.4%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
5.7%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
2.6%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Serious AEs
0%a
NCT00590122 · Phase 4 · registry result, not featured evidence
5.5%b
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
2%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.8%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.6%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
2.3%Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
15.6%Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
25%Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
1.1%
NCT01130493 · Phase 3 · registry result, not featured evidence
7%
NCT01096186 · Phase 3 · registry result, not featured evidence
0%
NCT00869791 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
dyskinesia 5%
nausea 0%
NCT00590122 · Phase 4 · registry result, not featured evidence
b
insomnia 3.5%
fall 3%
nausea 3%
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
390 mg LD
nausea 20.4% (placebo 8.7%)
headache 17.3% (placebo 10.9%)
dizziness 12.2% (placebo 5.4%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
245 mg LD
dizziness 19.2% (placebo 5.4%)
nausea 19.2% (placebo 8.7%)
headache 12.5% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
145 mg LD
nausea 13.8% (placebo 8.7%)
dizziness 9.2% (placebo 5.4%)
headache 6.9% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
nausea 11.6%
dyskinesia 7%
fall 7%
NCT01411137 · Phase 3 · registry result, not featured evidence
upper respiratory infection 15.6%
anxiety 6.3%
fall 6.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
fall 16.7%
orthostatic hypotension 16.7%
anxiety 8.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
dyskinesia 4.5%
confusional state 3.4%
insomnia 3.4%
NCT01130493 · Phase 3 · registry result, not featured evidence
insomnia 5.8%
dyskinesia 5.5%
fall 5.3%
NCT01096186 · Phase 3 · registry result, not featured evidence
anxiety 3.7%
fatigue 3.7%
feeling of warth in abdomen 3.7%
NCT00869791 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Parcopa

Time to 'ON Response 23.9 vs 28.5 Carbidopa/Levodopa minutes
absolute value · minutes
NCT00590122 · Phase 4 · registry result, not featured evidence

Rytary (IPX066)

Off" Time 23.82% (n=201) vs 29.79% (n=192) IR CD-LD @ 22wk
absolute value · percentage points
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
Off" Time 3.87 vs 4.88 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
3.82 vs 5.22 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
3.83 vs 5.83 IR CD-LD hours @ 1wk
NCT00869791 · Phase 2 · registry result, not featured evidence
On" Time Without Troublesome Dyskinesia 11.84 vs 10.91 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 1 more result
11.36 vs 9.98 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS II III Sum -14.9 vs -0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-12.9 vs -0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-11.7 vs -0.6 placebo score @ 30wk145mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PDQ-39 -6 vs 0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-3.8 vs 0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-4.4 vs 0.6 placebo score @ 30wk145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PGIC 5.2 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.4 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.3 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
CGI-C 5.5 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.7 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.6 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
PDQ-8 9.6 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 3 more results
8.1 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
8.5 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
9 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
Awake OFF Time 23.98% (n=83) vs 32.48% (n=83) CLE @ 2wk
absolute value · percentage points
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 29.3 vs 31.7 CLE score @ 2wk
absolute change · score
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 26.4 score @ 39wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence
UPDRS Total 30.5 score @ 39wk
absolute value · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Parcopa's landscape · Rytary (IPX066)'s landscape